QCG
MRNA icon

Quadrant Capital Group’s Moderna MRNA Stock Holding History

Quadrant Capital Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,194
Closed -$111K – 2060
2026
Q1 		$111K Buy
2,194
+402
+22% +$18.8K ﹤0.01% 1453
2025
Q4 		$52.8K Sell
1,792
-9,455
-84% -$257K ﹤0.01% 1663
2025
Q3 		$291K Buy
+11,247
New +$314K 0.01% 1143
2025
Q2 		– Sell
-4,262
Closed -$121K – 2111
2025
Q1 		$121K Buy
4,262
+1,742
+69% +$61.8K ﹤0.01% 1482
2024
Q4 		$105K Buy
2,520
+697
+38% +$33.3K 0.01% 1028
2024
Q3 		$122K Sell
1,823
-1,508
-45% -$138K 0.01% 958
2024
Q2 		$396K Buy
3,331
+415
+14% +$52.5K 0.03% 388
2024
Q1 		$311K Buy
2,916
+244
+9% +$24.6K 0.02% 455
2023
Q4 		$266K Buy
2,672
+187
+8% +$15.7K 0.02% 485
2023
Q3 		$257K Buy
2,485
+697
+39% +$77.7K 0.03% 429
2023
Q2 		$217K Sell
1,788
-438
-20% -$58.4K 0.02% 479
2023
Q1 		$342K Sell
2,226
-465
-17% -$76.7K 0.04% 357
2022
Q4 		$483K Buy
2,691
+986
+58% +$161K 0.05% 242
2022
Q3 		$202K Sell
1,705
-192
-10% -$29.1K 0.03% 427
2022
Q2 		$271K Sell
1,897
-38
-2% -$5.43K 0.04% 346
2022
Q1 		$333K Buy
1,935
+213
+12% +$35.9K 0.04% 323
2021
Q4 		$437K Sell
1,722
-47
-3% -$13.7K 0.05% 243
2021
Q3 		$681K Buy
1,769
+299
+20% +$110K 0.1% 151
2021
Q2 		$345K Buy
1,470
+134
+10% +$23.9K 0.05% 253
2021
Q1 		$175K Buy
1,336
+288
+27% +$41.7K 0.03% 389
2020
Q4 		$109K Buy
1,048
+423
+68% +$42.8K 0.02% 470
2020
Q3 		$44K Buy
625
+55
+10% +$3.83K 0.01% 701
2020
Q2 		$37K Sell
570
-1,225
-68% -$67.1K 0.01% 836
2020
Q1 		$54K Buy
+1,795
New +$41.3K 0.01% 851

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Quadrant Capital Group's MRNA Position: Q2 2026 in Review

Quadrant Capital Group sold out of Moderna (MRNA) in Q2 2026, closing a stake of 2,194 shares — an estimated $111K sold.

Quadrant Capital Group first reported a position in MRNA in Q1 2020 and held it in 24 quarters. The position peaked at $681K in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Quadrant Capital Group reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 2,194 Moderna shares in Q2 2026, an estimated $111K.
  • Quadrant Capital Group first reported a position in Moderna in Q1 2020 and held it in 24 quarters.
  • Quadrant Capital Group's Moderna position peaked at $681K in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.